BR112021016121A2 - Anticorpo isolado que se liga a tecidos tumorais, anticorpo que se liga ao tecido tumoral, método para induzir uma resposta imune, método para tratar um paciente com câncer com um tumor, método para identificar um paciente que tem um tumor, vetor de expressão, célula hospedeira, método para produzir um anticorpo, método para identificar um anticorpo com atividade antitumoral, uso de um anticorpo e polipeptídeo - Google Patents

Anticorpo isolado que se liga a tecidos tumorais, anticorpo que se liga ao tecido tumoral, método para induzir uma resposta imune, método para tratar um paciente com câncer com um tumor, método para identificar um paciente que tem um tumor, vetor de expressão, célula hospedeira, método para produzir um anticorpo, método para identificar um anticorpo com atividade antitumoral, uso de um anticorpo e polipeptídeo

Info

Publication number
BR112021016121A2
BR112021016121A2 BR112021016121A BR112021016121A BR112021016121A2 BR 112021016121 A2 BR112021016121 A2 BR 112021016121A2 BR 112021016121 A BR112021016121 A BR 112021016121A BR 112021016121 A BR112021016121 A BR 112021016121A BR 112021016121 A2 BR112021016121 A2 BR 112021016121A2
Authority
BR
Brazil
Prior art keywords
antibody
tumor
binds
identifying
tumor tissue
Prior art date
Application number
BR112021016121A
Other languages
English (en)
Inventor
Alexander Scholz
Amy Manning-Bog
Eric Emerling Daniel
Fengling Liu
Jeff Defalco
Jessica Finn
Nikhil Vad
Michael Greenberg Norman
M Lippow Shaun
Tito Serafini
Vera Huang
Wayne Volkmuth
H Robinson William
Chong Tan Yann
Original Assignee
Atreca Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atreca Inc filed Critical Atreca Inc
Publication of BR112021016121A2 publication Critical patent/BR112021016121A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

anticorpo isolado que se liga a tecidos tumorais, anticorpo que se liga ao tecido tumoral, método para induzir uma resposta imune, método para tratar um paciente com câncer com um tumor, método para identificar um paciente que tem um tumor, vetor de expressão, célula hospedeira, método para produzir um anticorpo, método para identificar um anticorpo com atividade antitumoral, uso de um anticorpo e polipeptídeo. são providos aqui os anticorpos que se ligam ao tecido tumoral por meio de uma interação de ligação com um complexo extracelular de proteína-rna. esses anticorpos são usados em métodos de indução de uma resposta imune e métodos de inibição do crescimento de células tumorais. além disso, são fornecidos métodos de produção de tais anticorpos.
BR112021016121A 2019-02-15 2020-02-14 Anticorpo isolado que se liga a tecidos tumorais, anticorpo que se liga ao tecido tumoral, método para induzir uma resposta imune, método para tratar um paciente com câncer com um tumor, método para identificar um paciente que tem um tumor, vetor de expressão, célula hospedeira, método para produzir um anticorpo, método para identificar um anticorpo com atividade antitumoral, uso de um anticorpo e polipeptídeo BR112021016121A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962806310P 2019-02-15 2019-02-15
US201962806285P 2019-02-15 2019-02-15
US201962843298P 2019-05-03 2019-05-03
US201962843751P 2019-05-06 2019-05-06
US201962852830P 2019-05-24 2019-05-24
US201962927501P 2019-10-29 2019-10-29
PCT/US2020/018350 WO2020168231A2 (en) 2019-02-15 2020-02-14 Antibodies that bind tumor tissue for diagnosis and therapy

Publications (1)

Publication Number Publication Date
BR112021016121A2 true BR112021016121A2 (pt) 2022-01-04

Family

ID=69845562

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016121A BR112021016121A2 (pt) 2019-02-15 2020-02-14 Anticorpo isolado que se liga a tecidos tumorais, anticorpo que se liga ao tecido tumoral, método para induzir uma resposta imune, método para tratar um paciente com câncer com um tumor, método para identificar um paciente que tem um tumor, vetor de expressão, célula hospedeira, método para produzir um anticorpo, método para identificar um anticorpo com atividade antitumoral, uso de um anticorpo e polipeptídeo

Country Status (19)

Country Link
US (2) US11472885B2 (pt)
EP (2) EP3806895B1 (pt)
JP (1) JP7365421B2 (pt)
KR (1) KR102592844B1 (pt)
CN (1) CN114040774A (pt)
AU (1) AU2020223356B2 (pt)
BR (1) BR112021016121A2 (pt)
CA (1) CA3129637A1 (pt)
DK (1) DK3806895T5 (pt)
ES (1) ES2956413T3 (pt)
FI (1) FI3806895T3 (pt)
IL (1) IL285541A (pt)
MX (1) MX2021009727A (pt)
NZ (1) NZ782502A (pt)
PL (1) PL3806895T3 (pt)
PT (1) PT3806895T (pt)
SG (1) SG11202108645YA (pt)
TW (1) TW202045542A (pt)
WO (1) WO2020168231A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3194607A1 (en) * 2020-10-05 2022-04-14 Brian D. O'DONOVAN Markers for the early detection of colon cell proliferative disorders
WO2022081843A1 (en) * 2020-10-15 2022-04-21 Atreca, Inc. Antibody scaffold structure
CN114895024A (zh) * 2021-07-01 2022-08-12 浙江大学 检测抗富含丝氨酸/精氨酸剪接因子9-IgG抗体的试剂盒
WO2023010057A1 (en) * 2021-07-28 2023-02-02 Atreca, Inc. Atrc-101 target expression assay

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261804B1 (en) * 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
CN1238366C (zh) 1997-01-21 2006-01-25 综合医院公司 利用rna－蛋白融合体筛选蛋白
WO2005040810A1 (en) * 2003-10-15 2005-05-06 Roche Diagnostics Gmbh Use of protein hnrnp-k as a marker for breast cancer
JP5026268B2 (ja) * 2004-06-10 2012-09-12 ヴィヴェンティア バイオテクノロジーズ インコーポレーティッド 腫瘍特異的抗体
CN104169419A (zh) 2011-12-23 2014-11-26 艾根股份有限公司 用于输送生物活性rna的组合物和方法
US20150011405A1 (en) * 2013-07-03 2015-01-08 Atreca, Inc. Use of Nanoexpression to Interrogate Antigen Repertoires
WO2017010568A1 (ja) * 2015-07-16 2017-01-19 国立大学法人京都大学 Ｒｎａ－タンパク質複合体とその使用

Also Published As

Publication number Publication date
US20230140035A1 (en) 2023-05-04
TW202045542A (zh) 2020-12-16
EP3806895A2 (en) 2021-04-21
KR102592844B1 (ko) 2023-10-20
PL3806895T3 (pl) 2024-02-19
US20200325242A1 (en) 2020-10-15
AU2020223356B2 (en) 2023-12-07
DK3806895T3 (da) 2023-07-24
FI3806895T3 (fi) 2023-09-13
WO2020168231A3 (en) 2020-09-24
KR20210139258A (ko) 2021-11-22
ES2956413T3 (es) 2023-12-20
EP3806895B1 (en) 2023-06-21
MX2021009727A (es) 2021-11-12
IL285541A (en) 2021-09-30
SG11202108645YA (en) 2021-09-29
US11472885B2 (en) 2022-10-18
AU2020223356A1 (en) 2021-10-07
NZ782502A (en) 2023-10-27
DK3806895T5 (da) 2024-08-19
EP4253422A3 (en) 2023-12-06
WO2020168231A2 (en) 2020-08-20
JP7365421B2 (ja) 2023-10-19
CA3129637A1 (en) 2020-08-20
PT3806895T (pt) 2023-07-27
EP4253422A2 (en) 2023-10-04
JP2022520479A (ja) 2022-03-30
CN114040774A (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
BR112021016121A2 (pt) Anticorpo isolado que se liga a tecidos tumorais, anticorpo que se liga ao tecido tumoral, método para induzir uma resposta imune, método para tratar um paciente com câncer com um tumor, método para identificar um paciente que tem um tumor, vetor de expressão, célula hospedeira, método para produzir um anticorpo, método para identificar um anticorpo com atividade antitumoral, uso de um anticorpo e polipeptídeo
MX2022009947A (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
BR112017007093A2 (pt) composições e métodos de uso para aumento da resposta imune e terapia do câncer
BR112019010943A8 (pt) Usos de um anticorpo que se liga especificamente ao domínio extracelular de tigit humano para a inibição do crescimento do tumor, composição que compreende o dito anticorpo, polinucleotídeo, vetor e célula
BR112019014615A2 (pt) Receptores de antígeno quimérico contra axl ou ror2 e métodos de uso dos mesmos
CY1124944T1 (el) Βελτιστοποιημενα αμφιειδικα αντισωματα αντι-cd3 και χρησεις αυτων
NZ754730A (en) Anti-icos agonist antibodies and uses thereof
MX2020004578A (es) Composiciones de casz y metodos de uso.
MX2022012409A (es) Celulas que presentan antigeno artificial manipulado por ingenieria para expansion linfocitica infiltrante de tumores.
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
MX2020003504A (es) Receptores de celulas t que reconocen p53 mutado.
BR112019005697A2 (pt) anticorpos anti-muc16-cd3 biespecíficos e conjugados de fármaco e anti-muc16
BR112013006699A2 (pt) vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
MX2017006624A (es) Anticuerpos contra cd73 y sus usos.
BR112022000371A2 (pt) Anticorpos claudin18 e métodos de tratamento contra câncer
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
PH12015502278A1 (en) Novel bispecific binding molecules with antitumoral activity
BR112017016336A2 (pt) proteínas de ligação icos agonistas?
MX2020003117A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
PE20200757A1 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
BR112021018608A2 (pt) Anticorpos para claudina-6 e conjugados de fármaco
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.